Brief: Orexo Acquires Exclusive U.S. Rights To Commercialize Deprexis

Orexo AB

11/05/2020 07:10

May 11 (Reuters) - Orexo AB  ORX.ST :
    * OREXO ACQUIRES EXCLUSIVE US RIGHTS TO COMMERCIALIZE
DEPREXIS®, A
WORLD-LEADING DIGITAL THERAPY TO HELP PATIENTS MANAGE THE
SYMPTOMS OF DEPRESSION
    * UNDER TERMS OF AGREEMENT, GAIA IS ENTITLED TO AN UPFRONT
PAYMENT
AND ROYALTIES WILL BE PAID BASED ON NET SALES FROM JANUARY 1,
2022 ONWARDS
    * ANNUAL NET SALES POTENTIAL OF DEPREXIS® ARE ESTIMATED TO
EXCEED
MARKET POTENTIAL OF VORVIDA® (USD 120 M - USD 200 M) AND OXD01
(USD 150 M - USD 225 M)
    * INVESTMENTS RELATED TO DEAL AND OPPORTUNITY TO ACCELERATE
LAUNCH
OF ALL OREXO'S DIGITAL THERAPIES WILL IMPACT OREXO'S CASH FLOW
WITH APPROXIMATELY SEK 115 MILLION IN Q2 AND RESULT IN AN
INCREASED OPEX FOR 2020
    * ACQUIRED EXCLUSIVE US RIGHTS TO GAIA AG'S (GAIA) DEPREXIS®

Source text for Eikon:  ID:nWkr47sT5r 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))